

Learner Notification

MED Learning Group

Updates and Best Practices Across Malignancies: Evaluating Therapeutic Developments and Optimizing Multidisciplinary Care Throughout the Spectrum Multiple Myeloma

August 31, 2023 – August 31, 2024

Online

Acknowledgement of Financial Commercial Support

Regeneron

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Assess updates in tumor assessment, including targetable mutations and considerations for eligibility with immunotherapeutic options for cancer management.
2. Explain the latest developments in therapeutics, including developments in novel targeted and immuno-therapeutic mechanisms, across malignancies.
3. Summarize best practices for monitoring and management of potential unique adverse events associated with novel therapeutics across oncology.
4. Evaluate best practices for integrating patient advocacy and optimal communication in oncology care.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Lauren	Bartunek	NA
Amer	Beitinjaneh	NA
Vaidehee	Deshpande	NA
Martin	Dietrich	AstraZeneca, BMS, Daiichi Sankyo, Regeneron, Sanofi, Boehringer Ingelheim, G1 Therapeutics: Consultant
Matthew	Frese	NA
Christina	Gallo	NA
Heather	Gee	NA
Mehdi	Hamadani	Incyte Corporation, MorphoSys, SeaGen, Gamida Cell, Novartis, Legend Biotech, Kadmon, ADC Therapeutics, Omeros, Abbvie, Cari: Consultant, Sanofi Genzyme, AstraZeneca, BeiGene,

		ADC, Therapeutics, Kite: Speakers Bureau, ADC Therapeutics, Spectrum Pharmaceuticals: Contracted Research Funding
Omid	Hamid	Alkermes, Amgen, Bactonix, Beigene, Bioatla, BMS, Esai Biotech, Roche Genentech, Georgiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, 10 Biotech, Iovance, Janssen, KSQ, Merck, Moderna, Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial Health Tech, Zelluna: Consultant, BMS, Immunocore, Novartis, Pfizer, Regeneron: Speakers Bureau, Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, Cytomx, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Pfizer, Regeneron, Seattle Genetics, Torque, Zelluna: Contracted Research Funding, Bactonix: Stock Shareholder
Maen	Hussein	IntegraConnect, Coherus Biosciences, Athenex, Karyopharm Therapeutics, BMS, AstraZeneca, Mirati Therapeutics, Exelixis, Biopharma, Abbvie, AstraZeneca, Oncocyte, Aptitude Health: Consultant
P. Connor	Johnson	AstraZeneca, Seagen, ADC Therapeutics: Consultant, AstraZeneca, Medically Home: Contracted Research
Nikhil	Khushalani	Regeneron, Merck, Iovance, Novartis, Nektar, Castle Biosciences, Instil Bio: Advisory Board, BMS, Merck, Novartis, GSK, HUYA Bioscience, Regeneron, Celgene, Replimmune, Modulation Therapeutics: Contracted Research. Asensus Surgical, Bellicum Pharmaceuticals: Stock Shareholder, AstraZeneca, Incyte: Data Safety Monitoring Board, BMS, Regeneron, Replimmune, Nektar: Study Steering Committee
Nicole	Longo	NA
Meredith	McKean	NA
Aimee	Meissner	NA
Joseph	Mikhael	Amgen, BMS, Janssen, Karyopharm, Sanofi, Takeda: Consultant
Anita	Misra-Press	NA
Cesar A.	Perez	Accutar Biotech, Kinnate Biopharma, Relay Therapeutics, Seagen Inc, Kura Oncology, Hymab Inc, XilioTherapeutics, Elucida Oncology, Tallac Therapeutics, Ribbon Therapeutics, Mirati Therapeutics, Elpiscience Biopharmaceuticals, Inc., Dracen Pharmaceuticals, Zhuhai Yufan Biotechnologies Co.: Research Support
Ingrid	Peterson	NA
Emily S.	Ruiz	Checkpoint Therapeutics, Regeneron Pharmaceuticals, Feldman Pharmaceuticals: Consultant, Regeneron, Merck, Castle Biosciences: Principal Investigator/Co-Investigator
Jo	Shultz	NA
Ann W.	Silk	UpToDate, Inc: Royalties, InStil Bio, Signatera, Merck: Consultant, Biohaven Pharmaceuticals, Replimune, Morphogenesis, Shattuck Laboratories: Contracted Research Funding
Judy S.	Wang	BioNTech, Janssen, Kanaph Therapeutics, Stemline Therapeutics/Menarini: Consultant, AstraZeneca, Eisai: Speaker's Bureau, Accutar Biotech, Adagene, Agenus, Artios, Astellas, AstraZeneca, Bayer, BeiGene, Bicycle Therapeutics, BioNTech, Black Diamond Therapeutics, Blueprint Medicines, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Coherus Biosciences, Compugen, Cyteir Therapeutics, Daiichi Sankyo, Erasca, Evelo Biosciences, Genentech, GSK, IGM, Immune-Onc Therapeutics, Immunitas Therapeutics, Immunogen, Jacobio, Janssen, Jazz Pharmaceuticals, Jounce, KLUS Pharma, Kymab, Loxo Oncology, MabSpace, Macrogenics, Merck, Moderna, ngmBIO, Nurix Therapeutics, Phoenix Molecular Designs, Pionyr Immunotherapeutics, Prelude Therapeutics, PureTech Health, Relay Therapeutics, Ribon Thearapeutics, Sanofi, Seven&Eight Biopharma, Stemline Therapeutics/Menarini, Step Pharma, Stingthera, Syndax, Taiho, Takeda, TeneoBio, Treadwell, Vedanta, Vigeo Therapeutics, Xencor, Zymeworks: Contracted Research Funding
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com